title: Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
abstract: Atopic dermatitis (AD) is an inflammatory skin disease commonly affecting children and managed by pediatricians, primary care physicians, allergists, and dermatologists alike. For many years, the only available topical pharmacological treatment was topical corticosteroids. This changed in 2000-2001, when topical formulations of two calcineurin inhibitors (tacrolimus and pimecrolimus) were approved for short-term or chronic intermittent treatment of AD in patients ≥ 2 years of age, in whom other treatments have been ineffective or contraindicated. These topical calcineurin inhibitors (TCIs) quickly became a popular treatment option due at least in part to concerns over adverse events associated with prolonged topical corticosteroid use, especially in children. However, based on theoretical concerns about a possible risk of lymphoma associated with TCI use, a Boxed Warning was placed on both products in 2006. Since then, despite an extensive body of evidence, no causal relationship has been demonstrated between TCI use and an increased risk of lymphoma; however, the US FDA has concluded that a link cannot be ruled out. In fact, based on post-marketing surveillance of spontaneous, literature, and solicited reports, we report here that the lymphoma incidence in the topical pimecrolimus-exposed population is up to approximately 54-fold less than that seen in the general US population. This review summarizes the mechanism of action of TCIs, the factors that prompted the Boxed Warning, and recent TCI safety and efficacy data. Based on these data, both topical corticosteroids and TCIs should have defined roles in AD management, with TCIs favored for sensitive skin areas (e.g., face) and instances where topical corticosteroids have proven ineffective, thereby minimizing the risk of adverse effects with both drug classes.
authors.affiliation: Allergy and Asthma Associates of Southern California, Southern California Research, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691, USA. wcarr@allergee.com
authors.forename: Warner W
authors.initials: WW
authors.lastname: Carr
mesh_terms: D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004348:Drug Labeling; D004643:Emollients / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced
chemical_list: D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D004643:Emollients; D005938:Glucocorticoids
references.citation: J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8
references.pmid: 16384751
references.citation: J Invest Dermatol. 2007 Apr;127(4):808-16
references.pmid: 17096020
references.citation: Pediatr Dermatol. 2008 Jan-Feb;25(1):117-20
references.pmid: 18304172
references.citation: J Dermatol Sci. 2009 May;54(2):76-87
references.pmid: 19303745
references.citation: Ann Dermatol. 2010 May;22(2):125-37
references.pmid: 20548901
references.citation: Am J Clin Dermatol. 2004;5(4):267-79
references.pmid: 15301573
references.citation: Pediatrics. 2007 Sep;120(3):e527-34
references.pmid: 17766497
references.citation: Ann Pharmacother. 2009 Dec;43(12):1956-63
references.pmid: 19903860
references.citation: Curr Med Res Opin. 2008 Apr;24(4):985-94
references.pmid: 18284804
references.citation: J Invest Dermatol. 2011 Jan;131(1):67-73
references.pmid: 20739951
references.citation: Br J Dermatol. 2011 Sep;165(3):465-73
references.pmid: 21466537
references.citation: J Allergy Clin Immunol. 2009 Dec;124(6):1251-8.e23
references.pmid: 20004783
references.citation: Dermatology. 2009;219(1):7-21
references.pmid: 19293564
references.citation: J Dermatolog Treat. 2010 May;21(3):144-56
references.pmid: 20394490
references.citation: Dermatol Clin. 2010 Jul;28(3):535-45
references.pmid: 20510763
references.citation: J Allergy Clin Immunol. 2005 Jun;115(6):1249-53
references.pmid: 15940142
references.citation: J Allergy Clin Immunol. 2009 May;123(5):1111-6, 116.e1-13
references.pmid: 19361841
references.citation: Drug Saf. 2008;31(3):185-98
references.pmid: 18302444
references.citation: Dermatol Online J. 2006 Oct 31;12(6):2
references.pmid: 17083882
references.citation: BMJ. 2005 Mar 5;330(7490):516
references.pmid: 15731121
references.citation: Lancet. 2003 Jan 11;361(9352):151-60
references.pmid: 12531593
references.citation: Int Arch Allergy Immunol. 2006;141(3):199-212
references.pmid: 16926539
references.citation: N Engl J Med. 2005 Jun 2;352(22):2314-24
references.pmid: 15930422
references.citation: Br J Dermatol. 1994 Sep;131(3):406-16
references.pmid: 7918017
references.citation: Curr Allergy Asthma Rep. 2006 Jul;6(4):270-4
references.pmid: 16822378
references.citation: MedGenMed. 2006 Oct 10;8(4):8
references.pmid: 17415290
references.citation: Dermatology. 2007;214(4):289-95
references.pmid: 17460399
references.citation: Curr Med Res Opin. 2011 Jul;27(7):1395-406
references.pmid: 21563877